1. Home
  2. BCDA vs MBIO Comparison

BCDA vs MBIO Comparison

Compare BCDA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • MBIO
  • Stock Information
  • Founded
  • BCDA N/A
  • MBIO 2015
  • Country
  • BCDA United States
  • MBIO United States
  • Employees
  • BCDA N/A
  • MBIO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCDA Health Care
  • MBIO Health Care
  • Exchange
  • BCDA Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • BCDA 7.9M
  • MBIO 7.3M
  • IPO Year
  • BCDA N/A
  • MBIO N/A
  • Fundamental
  • Price
  • BCDA $2.46
  • MBIO $2.77
  • Analyst Decision
  • BCDA Strong Buy
  • MBIO Strong Buy
  • Analyst Count
  • BCDA 1
  • MBIO 1
  • Target Price
  • BCDA $25.00
  • MBIO $100.00
  • AVG Volume (30 Days)
  • BCDA 54.8K
  • MBIO 395.3K
  • Earning Date
  • BCDA 03-26-2025
  • MBIO 03-10-2025
  • Dividend Yield
  • BCDA N/A
  • MBIO N/A
  • EPS Growth
  • BCDA N/A
  • MBIO N/A
  • EPS
  • BCDA N/A
  • MBIO N/A
  • Revenue
  • BCDA $71,000.00
  • MBIO N/A
  • Revenue This Year
  • BCDA N/A
  • MBIO N/A
  • Revenue Next Year
  • BCDA N/A
  • MBIO N/A
  • P/E Ratio
  • BCDA N/A
  • MBIO N/A
  • Revenue Growth
  • BCDA N/A
  • MBIO N/A
  • 52 Week Low
  • BCDA $1.63
  • MBIO $2.61
  • 52 Week High
  • BCDA $8.85
  • MBIO $74.50
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 49.50
  • MBIO 28.35
  • Support Level
  • BCDA $2.12
  • MBIO $2.61
  • Resistance Level
  • BCDA $2.73
  • MBIO $3.04
  • Average True Range (ATR)
  • BCDA 0.23
  • MBIO 0.79
  • MACD
  • BCDA 0.01
  • MBIO 0.00
  • Stochastic Oscillator
  • BCDA 35.82
  • MBIO 4.33

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: